Associated Papers
Systematic cysteine scanning identifies a druggable pocket in oncogenic KRAS.
van Tienen LM et al.
Cell Chemical Biology, 2026
Denitrogenative Alkylation of K-Ras(G12D) Inhibits Oncogenic Signaling in Cancer Cells.
Zheng Q et al.
Journal of the American Chemical Society, 2025
40587607 (PubMed )
Supplement: ja5c06745_si_001.pdf
A Facile Method to Engineer Mutant Kras Alleles in an Isogenic Cell Background.
Budagyan K et al.
Methods in Molecular Biology (clifton, N.j.), 2021
Oncogenic mutant RAS signaling activity is rescaled by the ERK/MAPK pathway.
Gillies TE et al.
Molecular Systems Biology, 2020
33073539 (PubMed )
Supplement: MSB-16-e9518-s004.zip › Gillies2020_SourceData_Fig4.pdf
Long-read sequencing for non-small-cell lung cancer genomes.
Sakamoto Y et al.
Genome Research, 2020
32887687 (PubMed )
Supplement: supp_gr.261941.120_Supplemental_material.docx
Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.
Egan C et al.
Haematologica, 2020
The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.
Goodwin J et al.
Nature Communications, 2017
28548087 (PubMed )
Supplement: ncomms15503-s1.pdf
Glycoproteomic Approach Identifies KRAS as a Positive Regulator of CREG1 in Non-small Cell Lung Cancer Cells.
Clark DJ et al.
Theranostics, 2016
[KRAS gene somatic mutations in Chilean patients with colorectal cancer].
Hurtado C et al.
Revista Medica De Chile, 2014
Select a paper to view details